SCHEMBL6054568

SCHEMBL6054568

CCc1ccc2nsnc2c1NC1=NCCN1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 14/20 0.67
ADRA2B P18089 13/20 0.67
ADRA2C P18825 13/20 0.67
ADRA1A P35348 8/20 0.67
LMNA P02545 4/20 0.67
HRH2 P25021 2/20 0.67
NISCH Q9Y2I1 2/20 0.67
HTR1D P28221 3/20 0.45
ADRA1D P25100 7/20 0.42
ADRA1B P35368 7/20 0.42
HTR1A P08908 2/20 0.42
CYP2D6 P10635 2/20 0.42
MEN1 O00255 1/20 0.42
SLC22A1 O15245 1/20 0.42
SLC22A3 O75751 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
OPRK1 P41145 1/20 0.42
KMT2A Q03164 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6054558 0.83 ADRA2A (0.72) ADRA2AADRA2BADRA2CADRA1ALMNA
Tizanidine SCHEMBL2471060 0.81 ADRA2A (0.79) ADRA2AADRA2BADRA2CADRA1ALMNA
Tizanidine SCHEMBL60334 0.81 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1ALMNA
SCHEMBL2615415 0.81 ADRA2A (0.72) ADRA2AADRA2BADRA2CADRA1ALMNA
SCHEMBL6054524 0.81 ADRA2A (0.72) ADRA2AADRA2BADRA2CADRA1ALMNA
Tizanidine SCHEMBL20769844 0.81 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1ALMNA
SCHEMBL6054569 0.80 ADRA2A (0.67) ADRA2AADRA2BADRA2CADRA1ALMNA
Tizanidine SCHEMBL23498010 0.80 ADRA2A (0.97) ADRA2AADRA2BADRA2CADRA1ALMNA
Tizanidine SCHEMBL41199 0.80 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1ALMNA
Tizanidine SCHEMBL6472652 0.80 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063813-A1 Organic compounds CRAWLEY PATRICK E 2006-03-23 US disclosed
EP-1556042-A2 COMBINATIONS OF BENZODITHIAZOLES AND COX-2 INHIBITORS FOR THE TREATMENT OF PAIN Novartis AG (CH) 2005-07-27 EP disclosed
WO-2004035030-A2 COMBINATIONS OF BENZODITHIAZOLES AND COX-2 INHIBITORS FOR THE TREATMENT OF PAIN NOVARTIS AG (CH) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063813-A1 Organic compounds PTGES2, PTGS2, PTGER2 ADRA2A 1059/4885ADRA2B 1064/4885ADRA2C 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.